A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
-
BUSINESS LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
-
ORGANIZATION JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
-
ORGANIZATION Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
-
BUSINESS DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
-
BUSINESS Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
-
BUSINESS Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
-
BUSINESS AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
-
BUSINESS Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
-
ORGANIZATION RAD-AR Council to Set Guidelines for Information Provisioning on Ethical Drugs
February 12, 2013
-
ORGANIZATION JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines
February 8, 2013
-
BUSINESS Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
-
REGULATORY NIHS to Accelerate Medical Innovation Research
February 7, 2013
-
BUSINESS Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
-
BUSINESS Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
-
BUSINESS Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
-
BUSINESS Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
-
BUSINESS Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
-
REGULATORY CRO Association to Compile Guidelines for Third-Party Outsourcing after GCP Revision
February 1, 2013
-
ORGANIZATION Wholesale Industry FTC Prohibits Drink Donations at Academic Confabs, Keeps Pace with Drug Makers
January 31, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…